查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413062

多重癌症篩檢市場：按樣本、測試類型、技術、癌症類型、最終用戶 - 2024-2030 年全球預測

Multicancer Screening Market by Sample (Blood, Saliva & Buccal Swab, Tissue), Test Type (In-vitro diagnostics (IVDs), Laboratory Developed Tests (LDTs)), Technology, Cancer Type, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年多篩檢市場規模為11.3億美元，預計2024年將達12.4億美元，2030年將達到21.1億美元，複合年成長率為9.30%。

全球多種癌症篩檢市場

主要市場統計
基準年[2023] 11.3億美元
預測年份 [2024] 12.4億美元
預測年份 [2030] 21.1億美元
複合年成長率（%） 9.3%
多重癌症篩檢市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估多癌症篩檢市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對多種癌症篩檢市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-多癌篩檢市場的市場規模和預測是多少？

2-在多癌症篩檢市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-多癌症篩檢市場的技術趨勢和法律規範是什麼？

4-多種癌症篩檢市場主要供應商的市場佔有率為何？

5-進入多癌篩檢市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率增加和人口老化
      • 對加強癌症早期檢測程序的需求激增
      • 多項政府措施促進醫療機構中的多種癌症篩檢
    • 抑制因素
      • 與多種癌症篩檢相關的昂貴且耗時的步驟
    • 機會
      • 液體活體組織切片的潛在用途和多個癌症檢測 (MCD) 研究中心的數量不斷增加
      • 活性化研發活動以開發癌症診斷和治療方法
    • 任務
      • 足夠的安全性和有效性資料以及對試驗表現變異性的擔憂
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章多種篩檢市場樣本

  • 血
  • 唾液和口腔拭子
  • 組織

第7章按測試類型分類的多種篩檢市場

  • 體外診斷（IVD）
  • 實驗室開發測試 (LDT)

第8章多種篩檢市場：依技術分類

  • 螢光原位雜合反應(FISH)
  • 免疫組織化學 (IHC)
  • 下一代定序（NGS）
  • 聚合酶鍊式反應 (PCR)

第9章按癌症類型分類的多種癌症篩檢市場

  • 大腦/神經系統
  • 乳房和婦科
  • 內分泌
  • 胃
  • 泌尿器官系統
  • 骨髓惡性腫瘤
  • 肺
  • 肉瘤
  • 皮膚

第 10 章 多種篩檢市場：依最終用戶分類

  • 學術/研究機構
  • 診斷和臨床實驗室
  • 醫院

第11章美洲多種癌症篩檢市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區多種篩檢市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲多癌症篩檢市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第15章競爭組合

  • 主要公司簡介
    • AnchorDx Medical Co., Ltd.
    • Anpac Bio-Medical Science Co., Ltd.
    • Burning Rock Biotech Limited
    • Caris Life Sciences
    • Delfi Diagnostics, Inc.
    • Elypta AB
    • EpiCypher, Inc.
    • Epigenomics AG
    • Exact Sciences Corporation
    • Foundation Medicine, Inc.
    • Freenome Holdings, Inc.
    • Grail, LLC by Illumina, Inc.
    • Guardant Health, Inc.
    • HLTH, INC.
    • Lucence Health Inc.
    • Micronoma, INC.
    • MiRXES Pte Ltd.
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • Naveris
    • StageZero Life Sciences. Ltd.
  • 主要產品系列

第16章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-5C6F41F5AFFC

[191 Pages Report] The Multicancer Screening Market size was estimated at USD 1.13 billion in 2023 and expected to reach USD 1.24 billion in 2024, at a CAGR 9.30% to reach USD 2.11 billion by 2030.

Global Multicancer Screening Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.13 billion
Estimated Year [2024] USD 1.24 billion
Forecast Year [2030] USD 2.11 billion
CAGR (%) 9.3%
Multicancer Screening Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multicancer Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multicancer Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include AnchorDx Medical Co., Ltd., Anpac Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Grail, LLC by Illumina, Inc., Guardant Health, Inc., HLTH, INC., Lucence Health Inc., Micronoma, INC., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, and StageZero Life Sciences. Ltd..

Market Segmentation & Coverage

This research report categorizes the Multicancer Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Sample
    • Blood
    • Saliva & Buccal Swab
    • Tissue
  • Test Type
    • In-vitro diagnostics (IVDs)
    • Laboratory Developed Tests (LDTs)
  • Technology
    • Fluorescence In-Situ Hybridization (FISH)
    • Immunohistochemistry (IHC)
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
  • Cancer Type
    • Brain/Nervous System
    • Breast & Gynecologic
    • Endocrine
    • Gastrointestinal
    • Genitourinary
    • Hematological Malignancies
    • Lung
    • Sarcoma
    • Skin
  • End User
    • Academic & Research Institutions
    • Diagnostic & Clinical Laboratories
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multicancer Screening Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multicancer Screening Market?

3. What are the technology trends and regulatory frameworks in the Multicancer Screening Market?

4. What is the market share of the leading vendors in the Multicancer Screening Market?

5. Which modes and strategic moves are suitable for entering the Multicancer Screening Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Multicancer Screening Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disease and rising aging population
      • 5.1.1.2. Surge in demand for enhanced early detection procedures of cancers
      • 5.1.1.3. Several government initiatives promoting multicancer screening in healthcare facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Time-consuming procedures coupled with high cost associated with multicancer screening
    • 5.1.3. Opportunities
      • 5.1.3.1. Potential utilization of liquid biopsy and rising multi-cancer detection (MCD) research centers
      • 5.1.3.2. Rising R&D activities for the development of cancer diagnostics treatment procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Concern associated with adequate safety and efficacy data and variability in test performance
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Multicancer Screening Market, by Sample

  • 6.1. Introduction
  • 6.2. Blood
  • 6.3. Saliva & Buccal Swab
  • 6.4. Tissue

7. Multicancer Screening Market, by Test Type

  • 7.1. Introduction
  • 7.2. In-vitro diagnostics (IVDs)
  • 7.3. Laboratory Developed Tests (LDTs)

8. Multicancer Screening Market, by Technology

  • 8.1. Introduction
  • 8.2. Fluorescence In-Situ Hybridization (FISH)
  • 8.3. Immunohistochemistry (IHC)
  • 8.4. Next-Generation Sequencing (NGS)
  • 8.5. Polymerase Chain Reaction (PCR)

9. Multicancer Screening Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Brain/Nervous System
  • 9.3. Breast & Gynecologic
  • 9.4. Endocrine
  • 9.5. Gastrointestinal
  • 9.6. Genitourinary
  • 9.7. Hematological Malignancies
  • 9.8. Lung
  • 9.9. Sarcoma
  • 9.10. Skin

10. Multicancer Screening Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Diagnostic & Clinical Laboratories
  • 10.4. Hospitals

11. Americas Multicancer Screening Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Multicancer Screening Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Multicancer Screening Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. AnchorDx Medical Co., Ltd.
    • 15.1.2. Anpac Bio-Medical Science Co., Ltd.
    • 15.1.3. Burning Rock Biotech Limited
    • 15.1.4. Caris Life Sciences
    • 15.1.5. Delfi Diagnostics, Inc.
    • 15.1.6. Elypta AB
    • 15.1.7. EpiCypher, Inc.
    • 15.1.8. Epigenomics AG
    • 15.1.9. Exact Sciences Corporation
    • 15.1.10. Foundation Medicine, Inc.
    • 15.1.11. Freenome Holdings, Inc.
    • 15.1.12. Grail, LLC by Illumina, Inc.
    • 15.1.13. Guardant Health, Inc.
    • 15.1.14. HLTH, INC.
    • 15.1.15. Lucence Health Inc.
    • 15.1.16. Micronoma, INC.
    • 15.1.17. MiRXES Pte Ltd.
    • 15.1.18. Myriad Genetics, Inc.
    • 15.1.19. Natera, Inc.
    • 15.1.20. Naveris
    • 15.1.21. StageZero Life Sciences. Ltd.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. MULTICANCER SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. MULTICANCER SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MULTICANCER SCREENING MARKET DYNAMICS
  • FIGURE 7. MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2023 VS 2030 (%)
  • FIGURE 8. MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 10. MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 12. MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 14. MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 26. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 6. MULTICANCER SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MULTICANCER SCREENING MARKET SIZE, BY SALIVA & BUCCAL SWAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MULTICANCER SCREENING MARKET SIZE, BY TISSUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. MULTICANCER SCREENING MARKET SIZE, BY IN-VITRO DIAGNOSTICS (IVDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TESTS (LDTS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 13. MULTICANCER SCREENING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION (FISH), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. MULTICANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. MULTICANCER SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. MULTICANCER SCREENING MARKET SIZE, BY BRAIN/NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. MULTICANCER SCREENING MARKET SIZE, BY BREAST & GYNECOLOGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. MULTICANCER SCREENING MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. MULTICANCER SCREENING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. MULTICANCER SCREENING MARKET SIZE, BY GENITOURINARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. MULTICANCER SCREENING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. MULTICANCER SCREENING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. MULTICANCER SCREENING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. MULTICANCER SCREENING MARKET SIZE, BY SKIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. MULTICANCER SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC & CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY SAMPLE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 241. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. MULTICANCER SCREENING MARKET LICENSE & PRICING